Thyroid Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Papillary Carcinoma, Follicular Carcinoma, Others), By Technique (Blood Test, Imaging, Biopsy, Others), By End-use (Hospital Laboratories, Cancer Diagnostic Centers, Research Institutes, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 2.73 Billion
CAGR (2026-2031)	4.33%
Fastest Growing Segment	Papillary Carcinoma
Largest Market	North America
Market Size (2031)	USD 3.52 Billion

Market Overview

The Global Thyroid Cancer Diagnostics Market will grow from USD 2.73 Billion in 2025 to USD 3.52 Billion by 2031 at a 4.33% CAGR. Thyroid cancer diagnostics comprise a suite of clinical evaluations including high resolution imaging, fine needle aspiration biopsy, and molecular genomic testing intended to detect and characterize thyroid malignancies. The primary drivers fueling this market are the growing global prevalence of endocrine disorders and the heightened demand for early disease detection to optimize therapeutic outcomes. The expanding burden of disease necessitates robust screening protocols, directly boosting the adoption of specialized diagnostic modalities. According to the American Cancer Society, in 2025, there were approximately 44,020 new cases of thyroid cancer diagnosed in the United States. This significant incidence rate underscores the critical need for precise diagnostic tools to manage the patient volume effectively.

Despite the market's expansion, a major challenge persists regarding the overdiagnosis of indolent thyroid nodules which often leads to unnecessary surgical interventions and overtreatment. This clinical issue has prompted regulatory bodies to revise screening guidelines, advocating for more conservative management of small and low risk nodules. Such shifts in clinical practice can create uncertainty around reimbursement and reduce the volume of diagnostic procedures performed for minor cases, thereby impeding broader market growth.

Key Market Drivers

The rising global incidence of thyroid cancer acts as a primary catalyst for the diagnostics market, necessitating robust screening protocols to manage the increasing patient volume. This surge is particularly evident in younger demographics, compelling healthcare systems to expand their diagnostic capabilities for earlier intervention. According to the World Health Organization's International Agency for Research on Cancer, November 2025, in the 'Thyroid cancer in adolescents and young adults' study, thyroid cancer accounted for more than 237,000 new cases globally among adolescents and young adults in 2022. This growing burden is mirrored at the national level in key markets. For instance, according to Cancer Research UK, as highlighted in September 2025, approximately 4,000 new thyroid cancer cases are diagnosed each year in the region, underscoring the persistent need for effective detection strategies across diverse populations.

Concurrently, the increasing adoption of molecular diagnostics and genomic profiling is transforming clinical workflows by addressing the challenge of indeterminate thyroid nodules. These advanced genomic classifiers allow clinicians to distinguish between benign and malignant nodules with greater accuracy, thereby reducing the frequency of unnecessary diagnostic surgeries and optimizing resource allocation. This shift towards precision medicine is evidenced by the substantial uptake of specialized testing solutions. According to Veracyte, February 2025, in the 'Fourth Quarter and Full Year 2024 Financial Results', the company reported that its Afirma genomic test volume grew by 12% to more than 60,000 tests for the full year 2024. Such robust adoption rates indicate that molecular testing is rapidly becoming a standard of care, driving market revenue through higher-value diagnostic procedures.

Download Free Sample Report

Key Market Challenges

The primary challenge hampering the growth of the thyroid cancer diagnostics market is the clinical shift addressing the overdiagnosis of indolent thyroid nodules. Historically, the detection of minute and low-risk nodules prompted aggressive diagnostic workups, but emerging practice standards now favor active surveillance over immediate fine needle aspiration biopsy or molecular testing for small lesions. This transition toward conservative management directly reduces the frequency of diagnostic procedures, thereby contracting the volume of tests performed and limiting revenue opportunities for diagnostic providers.

This reduction in procedural volume creates a difficult environment for market expansion as healthcare systems tighten reimbursement criteria to avoid unnecessary costs associated with low-risk cases. According to the Canadian Cancer Society, in 2025, an estimated 6,900 people in Canada will be diagnosed with thyroid cancer. While this incidence contributes to the patient pool, the increasing discernment in clinical guidelines means that a smaller percentage of individuals with thyroid nodules will undergo comprehensive diagnostic profiling. Consequently, companies face restricted utilization of premium diagnostic tools, as providers reserve these advanced modalities strictly for high-risk malignancies rather than routine screening of minor nodules.

Key Market Trends

The Integration of Artificial Intelligence and Machine Learning in Imaging is fundamentally reshaping thyroid cancer detection by enhancing the accuracy of ultrasound assessments and streamlining clinical workflows. AI algorithms are increasingly deployed to analyze sonographic features, helping clinicians differentiate between benign and malignant nodules with higher precision than conventional visual interpretation alone. This technological advancement directly addresses the variability in operator performance and significantly improves practice efficiency. According to RamSoft, September 2025, in the 'RamSoft Partners with Koios Medical' press release, the integration of the Koios DS AI software into radiology platforms enables clinics to achieve 49% less interpretation time while increasing patient throughput. By reducing the time required for image analysis, these tools allow healthcare providers to manage rising patient volumes more effectively while maintaining diagnostic confidence.

Simultaneously, the Growth of Companion Diagnostics for Targeted Therapies is driving the expansion of rapid next-generation sequencing (NGS) applications for advanced thyroid malignancies. As novel therapies targeting specific mutations like RET and BRAF become standard, there is a critical need for fast and comprehensive genomic profiling to guide treatment decisions immediately after diagnosis. This trend moves beyond simple nodule classification, focusing instead on identifying actionable alterations in aggressive cancers to optimize therapeutic strategies. According to CAP TODAY, August 2025, in the 'Introduction of a new FDA approved rapid NGS solution' report, the newly approved Oncomine Dx Express Test can deliver companion diagnostic results from tissue samples in as fast as 24 hours. This acceleration in turnaround time ensures that patients with high-risk thyroid cancer can access personalized treatment regimens without significant delays, improving overall care coordination.

Segmental Insights

The Papillary Carcinoma segment currently represents the fastest-growing category within the Global Thyroid Cancer Diagnostics Market, primarily due to the rising global incidence of this specific subtype. Data from established organizations such as the American Cancer Society indicates that papillary carcinoma accounts for the majority of confirmed thyroid malignancies, thereby driving a substantial volume of clinical testing. This segment growth is further accelerated by the increasing adoption of molecular diagnostic tests designed to identify specific genetic markers associated with the disease, ensuring more accurate detection and supporting the sustained demand for targeted diagnostic solutions.

Regional Insights

North America holds the leading position in the Global Thyroid Cancer Diagnostics Market, driven by a well-established healthcare infrastructure and high awareness regarding early disease detection. This dominance is supported by the presence of key industry players and increased research and development activities within the United States and Canada. Additionally, favorable regulatory environments, such as streamlined approval processes by the U.S. Food and Drug Administration, encourage the introduction of new diagnostic technologies. Robust reimbursement frameworks also facilitate patient access to essential testing services, consolidating the region's market leadership.

Recent Developments

• In September 2025, Interpace Biosciences presented new clinical data at the 2025 American Thyroid Association Annual Meeting regarding its thyroid cancer diagnostic solutions. The company showcased two scientific posters that validated the real-world utility of its combined testing platform, which includes ThyGeNEXT and ThyraMIRv2. The research demonstrated that the use of archival cytology slides allowed for successful molecular analysis in cases previously deemed insufficient, thereby reducing the need for repeat biopsies. The data further supported the test's ability to refine risk stratification for indeterminate thyroid nodules, particularly in cases with specific mutation profiles.
• In June 2024, Veracyte presented new research findings at the ENDO 2024 conference demonstrating the expanded prognostic capabilities of its Afirma Genomic Resource for Intelligent Discovery (GRID) tool. The study data indicated that the molecular testing platform could identify specific markers associated with aggressive thyroid disease and help rule out significant tumor invasion or lymph node metastases. These insights were derived from whole-transcriptome analysis, allowing for a more granular understanding of thyroid tumor biology beyond standard classification. The company emphasized that these advancements enabled clinicians to further personalize treatment plans for patients with thyroid nodules and cancer.
• In March 2024, Sonic Healthcare USA opened a new, custom-designed laboratory in Rye Brook, New York, dedicated to advanced thyroid cancer diagnostics. The facility was established to bring the testing for the ThyroSeq Genomic Classifier in-house, following an exclusive licensing agreement with the University of Pittsburgh Medical Center. The 21,000-square-foot laboratory was equipped with next-generation sequencing technology to streamline the processing of thyroid nodule samples. This operational expansion aimed to enhance the company's diagnostic capabilities, providing faster and more accurate malignancy risk assessments for patients with indeterminate thyroid nodules to guide clinical decision-making.
• In February 2024, GE HealthCare unveiled its enhanced LOGIQ ultrasound portfolio, which integrated a new third-party application specifically for thyroid diagnostics. Through a collaboration with PIUR IMAGING, the company introduced a 3D imaging solution known as "PIUR tUS inside" within its new AppAPI ecosystem. This tool was designed to automatically segment the thyroid, generate three-dimensional renderings, and measure nodules to assist clinicians in accurately diagnosing thyroid conditions. The launch highlighted the company's strategic focus on incorporating artificial intelligence and digital workflow tools to improve diagnostic precision and classification efficiency in the management of thyroid cancer.

Key Market Players

• F Hoffmann-La Roche AG
• Abbott Laboratories Inc
• Thermo Fisher Scientific Inc
• General Electric Co
• Siemens Healthcare GmbH
• Bio-Rad Laboratories Inc
• Toshiba Corporation
• Koninklijke Philips NV
• Agilent Technologies Inc

By Type	By Technique	By End-use	By Region
Papillary Carcinoma Follicular Carcinoma Others	Blood Test Imaging Biopsy Others	Hospital Laboratories Cancer Diagnostic Centers Research Institutes Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Thyroid Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Thyroid Cancer Diagnostics Market, By Type:

• Papillary Carcinoma
• Follicular Carcinoma
• Others

• Thyroid Cancer Diagnostics Market, By Technique:

• Blood Test
• Imaging
• Biopsy
• Others

• Thyroid Cancer Diagnostics Market, By End-use:

• Hospital Laboratories
• Cancer Diagnostic Centers
• Research Institutes
• Others

• Thyroid Cancer Diagnostics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE